Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.04 - $206.70
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.46M
Market Cap
$19.39B
Enterprise Value$22.26B
Total Cash (Recent Filing)$2.76B
Total Debt (Recent Filing)$6.59B
Price to Earnings (P/E)12.6
Beta0.63
Next Earnings
Oct 22, 2025EPS Estimate
3.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.47
Shares Outstanding146,614,600
10 Day Avg. Volume1,330,808
30 Day Avg. Volume1,464,671
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.23
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda7.97
Forecast
1Y Price Target
$169.81Price Target Upside21.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA has approved a subcutaneous autoinjector formulation of Leqembi for maintenance dosing to treat Alzheimer's disease, which is seen as a positive development for the stock.
Sales PerformanceLeqembi sales for 2Q beats consensus with an impressive performance across regions.
Bears Say
Competitive ThreatsLEQEMBI is seen as building a market that eventually gets swept away by either the safer antibodies or mAbs equipped with a BBB shuttle domain.
Pricing ConcernsThe annual list price for Leqembi SQ maintenance is 40-50% higher than the annualized price of IV maintenance therapy, though it is lower than the price of IV initiation.
Biogen News
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $206.70 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $19.39B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Oct 22, 2025 which is in 49 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Jul 31, 2025. The company reported $5.47 earnings per share for the quarter, beating the consensus estimate of $3.899 by $1.571.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.84.
How many shares outstanding does Biogen have?
Biogen has 146,614,600 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $5.47 in its last earnings report, beating expectations of $3.899. Following the earnings report the stock price went up 1.074%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
Biogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$169.81 (21.61% Upside)
$169.81 (21.61% Upside)
Blogger Sentiment
Neutral
BIIB Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 124.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $369.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.44%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
5.69%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Company Deck
BIIB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biogen's earnings call reflected strong product growth and a positive outlook, particularly with new product launches and pipeline advancements. Despite some challenges in the MS market and a partnership arbitration, the overall performance and strategic direction suggest a positive sentiment.View all BIIB earnings summariesBIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
BIIB Stock 12 Month Forecast
Average Price Target
$169.81
▲(21.61% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
32.35% Mutual Funds
20.25% Other Institutional Investors
15.14% Public Companies and Individual Investors